MX2012013264A - Quimeras ospa y su uso en vacunas. - Google Patents

Quimeras ospa y su uso en vacunas.

Info

Publication number
MX2012013264A
MX2012013264A MX2012013264A MX2012013264A MX2012013264A MX 2012013264 A MX2012013264 A MX 2012013264A MX 2012013264 A MX2012013264 A MX 2012013264A MX 2012013264 A MX2012013264 A MX 2012013264A MX 2012013264 A MX2012013264 A MX 2012013264A
Authority
MX
Mexico
Prior art keywords
ospa
chimeric molecules
quimeras
vaccines
serotype
Prior art date
Application number
MX2012013264A
Other languages
English (en)
Other versions
MX340739B (es
Inventor
Brian A Crowe
Ian Livey
Maria O'rourke
Michael Schwendinger
John J Dunn
Benjamin J Luft
Original Assignee
Brookhaven Science Ass Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brookhaven Science Ass Llc filed Critical Brookhaven Science Ass Llc
Publication of MX2012013264A publication Critical patent/MX2012013264A/es
Publication of MX340739B publication Critical patent/MX340739B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La invención se refiere al desarrollo de moléculas quiméricas OspA para su usarse contra la enfermedad de Lyme o vacuna contra borreliosis. Más específicamente, las moléculas quiméricas OspA comprenden la porción próxima de un serotipo de OspA, junto con la porción distal de otro serotipo de OspA, mientras que conserva las propiedades antigénicas de ambos de los polipéptidos parentales. Las moléculas quiméricas OspA se suministran solas o en combinación para proporcionar una protección contra una variedad de genoespecies de Borrelia.
MX2012013264A 2010-05-14 2011-05-13 Quimeras ospa y su uso en vacunas. MX340739B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
PCT/US2011/036533 WO2011143623A1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Publications (2)

Publication Number Publication Date
MX2012013264A true MX2012013264A (es) 2014-12-05
MX340739B MX340739B (es) 2016-07-22

Family

ID=44121257

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012013264A MX340739B (es) 2010-05-14 2011-05-13 Quimeras ospa y su uso en vacunas.
MX2012013261A MX348113B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.
MX2017006896A MX375965B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2012013261A MX348113B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.
MX2017006896A MX375965B (es) 2010-05-14 2011-05-13 Genes ospa quimericos, proteinas, y metodos para usar los mismos.

Country Status (13)

Country Link
US (6) US8623375B2 (es)
EP (4) EP2569009B1 (es)
JP (6) JP6030052B2 (es)
KR (7) KR20130062954A (es)
CN (3) CN103108652B (es)
AU (2) AU2011252844B2 (es)
BR (2) BR112012027315B1 (es)
CA (2) CA2799181C (es)
MX (3) MX340739B (es)
PL (2) PL2569008T3 (es)
RU (2) RU2583289C2 (es)
SI (2) SI2569008T1 (es)
WO (2) WO2011143623A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011252844B2 (en) 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
WO2012054786A1 (en) 2010-10-20 2012-04-26 Playspan Inc. Flexible monetization service apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
WO2013090611A2 (en) * 2011-12-13 2013-06-20 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
AU2013293448A1 (en) * 2012-07-27 2015-02-05 Baxalta GmbH Compositions comprising chimeric OspA molecules and methods of use thereof
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
US20140296139A1 (en) * 2013-03-15 2014-10-02 The Regents Of The University Of California Mitochondrial-derived peptide mots3 regulates metabolism and cell survival
US20160213766A1 (en) * 2013-09-23 2016-07-28 Ventria Bioscience, Inc. OspA Fusion Protein for Vaccination against Lyme Disease
HUE043779T2 (hu) 2014-01-09 2019-09-30 Valneva Austria Gmbh Az OspA mutáns fragmensei, valamint az ezzel kapcsolatos módszerek és alkalmazások
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
EP4108256A1 (en) * 2014-08-11 2022-12-28 University of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
JP6603400B2 (ja) * 2015-08-14 2019-11-06 テレフオンアクチーボラゲット エルエム エリクソン（パブル） パケットデータネットワーク接続を管理するためのノード及び方法
KR20210117359A (ko) * 2016-11-07 2021-09-28 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
US12018054B2 (en) 2017-04-13 2024-06-25 Valneva Austria Gmbh Multivalent OspA polypeptides and methods and uses relating thereto
KR20210018205A (ko) * 2018-04-03 2021-02-17 사노피 항원성 OspA 폴리펩타이드
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
WO2019195314A2 (en) 2018-04-03 2019-10-10 Sanofi Antigenic epstein barr virus polypeptides
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
EP4132950A1 (en) 2020-04-09 2023-02-15 Valneva Austria GmbH Compositions comprising three ospa fusion proteins for medical use
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
EP4262860A4 (en) 2020-12-17 2025-11-12 Idexx Lab Inc DETECTION AND TREATMENT OF ROCKY MOUNTAIN SPRINKLE FEVER
US20240368654A1 (en) * 2021-06-07 2024-11-07 University Of Massachusetts Apparatus and method for continuous production of rna
CN119173446A (zh) 2022-03-08 2024-12-20 赤盾医疗有限公司 机器人药物制备系统中的流体转移站
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2084413A1 (en) 1990-06-15 1991-12-16 Richard A. Flavell Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
FI933580A7 (fi) 1991-02-15 1993-10-13 Uab Research Foundation Pneumokokkiproteiinin rakennegeeni
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US6113914A (en) * 1991-08-15 2000-09-05 Smithkline Beecham Biologicals (S.A.) Osp A proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
AU8127494A (en) 1993-11-01 1995-05-23 Associated Universities, Inc. Chimeric proteins comprising borrelia polypeptides: uses therefor
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
EP0880360B1 (en) 1996-02-12 2002-10-09 Cobra Therapeutics Limited Novel methods of vaccination and vaccines therefore comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
US6660274B2 (en) * 1997-06-30 2003-12-09 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
AU2001281145A1 (en) * 2000-08-18 2002-03-04 Brookhaven Sciences Associates, Llc Recombinant constructs of borrelia burgdorferi
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
ATE381575T1 (de) * 2000-08-18 2008-01-15 Univ New York State Res Found Veränderte borrelia burgdorferi ospa
WO2004089969A2 (en) 2003-04-02 2004-10-21 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
BRPI0409459A (pt) * 2003-04-16 2006-05-02 Wyeth Corp novas composições imunogênicas para a prevenção e tratamento de doença meningocócica
MY148656A (en) * 2004-03-24 2013-05-15 Merck Sharp & Dohme Optimized expression of hpv 52 l1 in yeast.
US8821893B2 (en) 2004-07-02 2014-09-02 Bio Peptides, Corp. Oral vaccine for Borrelia
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
JP5390189B2 (ja) * 2005-11-29 2014-01-15 ヴァージニア コモンウェルス ユニバーシティ 多価キメラｏｓｐｃワクシノーゲンおよび診断用抗原
JP2010503384A (ja) 2006-09-15 2010-02-04 インターセル アーゲー ボレリア（Ｂｏｒｒｅｌｉａ）抗原
ATE496935T1 (de) 2007-02-22 2011-02-15 Baxter Int Verfahren zur aufreinigung hydrophober proteine
CA2690708A1 (en) * 2007-06-26 2008-12-31 Glaxosmithkline Biologicals S.A. Vaccine
KR101686942B1 (ko) * 2008-01-11 2016-12-28 이노비오 파마수티컬즈, 인크. 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신
US20110105355A1 (en) 2008-04-22 2011-05-05 Research Foundation Of State University Of New York Borrelia burgdorferi cell envelope protein array
US20110262475A1 (en) 2008-05-02 2011-10-27 Earnhart Christopher G Lyme disease vaccine
AU2011252844B2 (en) * 2010-05-14 2014-07-03 Baxalta GmbH Chimeric OspA genes, proteins, and methods of use thereof
AU2013293448A1 (en) * 2012-07-27 2015-02-05 Baxalta GmbH Compositions comprising chimeric OspA molecules and methods of use thereof

Also Published As

Publication number Publication date
AU2011252850B2 (en) 2016-03-17
EP3705133A2 (en) 2020-09-09
US20110293652A1 (en) 2011-12-01
BR112012029058A2 (pt) 2020-06-23
KR20200024354A (ko) 2020-03-06
KR20130062954A (ko) 2013-06-13
CN107641151A (zh) 2018-01-30
US11305000B2 (en) 2022-04-19
US9895434B2 (en) 2018-02-20
WO2011143617A1 (en) 2011-11-17
AU2011252850A1 (en) 2012-11-29
KR102130584B1 (ko) 2020-07-07
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
CN103118701B (zh) 2017-10-24
CN103108652B (zh) 2016-05-11
JP2018150386A (ja) 2018-09-27
CN103108652A (zh) 2013-05-15
RU2012153752A (ru) 2014-06-20
RU2012153972A (ru) 2014-06-20
JP2013529077A (ja) 2013-07-18
US9334311B2 (en) 2016-05-10
CA2799181A1 (en) 2011-11-17
RU2583289C2 (ru) 2016-05-10
KR102230562B1 (ko) 2021-03-22
CA2799181C (en) 2023-10-24
JP6965417B2 (ja) 2021-11-10
KR20190027955A (ko) 2019-03-15
KR20180031814A (ko) 2018-03-28
EP2569008B1 (en) 2019-12-25
EP3705133A3 (en) 2021-01-06
US9303073B2 (en) 2016-04-05
MX375965B (es) 2025-03-07
EP2569009B1 (en) 2019-10-09
BR112012027315A2 (pt) 2016-11-16
BR112012029058B1 (pt) 2022-03-29
KR20130133120A (ko) 2013-12-06
CA2798331A1 (en) 2011-11-17
RU2017138652A (ru) 2019-02-11
MX348113B (es) 2017-05-29
US8623375B2 (en) 2014-01-07
KR102222869B1 (ko) 2021-03-04
JP2013529078A (ja) 2013-07-18
AU2011252844A1 (en) 2012-11-29
EP2569008A1 (en) 2013-03-20
MX2012013261A (es) 2013-04-19
KR20200084062A (ko) 2020-07-09
AU2011252844B2 (en) 2014-07-03
US20140141029A1 (en) 2014-05-22
SI2569008T1 (sl) 2020-02-28
JP6030052B2 (ja) 2016-11-24
US20140141030A1 (en) 2014-05-22
JP2016171816A (ja) 2016-09-29
JP2020178719A (ja) 2020-11-05
EP2569009A1 (en) 2013-03-20
JP6227407B2 (ja) 2017-11-08
WO2011143623A1 (en) 2011-11-17
US20180296656A1 (en) 2018-10-18
RU2636455C2 (ru) 2017-11-23
US20160235830A1 (en) 2016-08-18
PL2569009T3 (pl) 2020-06-15
CN103118701A (zh) 2013-05-22
US8623376B2 (en) 2014-01-07
KR102085465B1 (ko) 2020-03-05
CA2798331C (en) 2022-03-15
CN107641151B (zh) 2021-10-01
JP2016168057A (ja) 2016-09-23
RU2017138652A3 (es) 2021-03-15
EP3705133B1 (en) 2024-06-26
KR20180082633A (ko) 2018-07-18
US20120020973A1 (en) 2012-01-26
MX340739B (es) 2016-07-22
EP3650041A1 (en) 2020-05-13
BR112012027315B1 (pt) 2021-08-17
BR112012027315A8 (pt) 2020-09-01

Similar Documents

Publication Publication Date Title
MX2012013264A (es) Quimeras ospa y su uso en vacunas.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
CL2015002941A1 (es) Usos terapéuticos de empaglifozina
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
BR112013018416A2 (pt) dispositivos médicos infláveis
HUE042825T2 (hu) Citidin-analógokat tartalmazó orális készítmények, és eljárás azok alkalmazására
IL216550A (en) Immunomodulatory agent-polymeric compounds, compositions comprising them, methods for their production and their uses
ECSP13011139A (es) Anticuerpos contra la angiopoyetina 2 humana
CL2013001104A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt2 y una insulina; y uso para tratar una enfermedad o afeccion tal como diabetes mellitus, diabetes mellitus tipo 1 y 2, entre otras.
CO6781540A2 (es) Protéinas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae
BR112014031244A2 (pt) dispositivo, conjunto médico, método para criação de um canal em um tecido mole biológico, método para redução da pressão intraocular, e dispositivo para uso na redução de pressão intraocular
BRPI1015283A2 (pt) composições para tingimento de queratina que compreendem um eliminador de radicais e uso das mesmas.
BRPI0910760A2 (pt) método para remineralizar tecido, agente remineralizador, e, kit
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
WO2014018274A8 (en) Compositions comprising chimeric ospa molecules and methods of use thereof
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
CL2011003043A1 (es) Composicion para proteger sujeto contra serotipo de virus del dengue que comprende al menos dos serotipos de virus dengue; sistema para administrar una composicion de vacuna del dengue; kit de vacuna porque comprende al menos una composicion de vacuna contra el virus del dengue.
CL2013001877A1 (es) Composicion inmunogenica que comprende un virus de diarrea viral bovina tipo 1b vivo modificado y un portador veterinario aceptable; vacuna que la comprende; y su uso para prevenir, tratar, manejar o aliviar uno o mas sintomas de una enfermedad causada por pestivirus.
BR112015020079A2 (pt) composições para cuidado oral
MX2013013393A (es) Composiciones de cuidado oral.
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
BRPI0910476A2 (pt) composições de vacinas para tratamento de febre do dengue e seus usos
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
BR112013019924A8 (pt) Composições para cuidado oral

Legal Events

Date Code Title Description
FG Grant or registration